Drug stocks are already outperforming: Over the past 12 months, the S&P 500 Pharmaceutical and Life Sciences Index’s total return of 29 per cent outpaced the S&P 500 by seven percentage points. Much of the outperformance occurred this year; the Pharma index climbed 8.7 per cent relative to the S&P 500’s 1.8 per cent.